Company intelligence / Profile preview

FRIZ Biochem

Ownership: Private
Development stage: Other

Overview

FRIZ Biochem has developed two patented technology platforms—CYCLE® Dx and Lab-direct—that enable rapid, secure, multiplexed molecular diagnostic testing at the point of care. Their COVID‑19 direct RT-PCR kits are CE-certified and designed for fast detection of SARS-CoV‑2 RNA without complex sample preparation. The company also offers custom oligonucleotides, phosphoramidites, and gold nanoparticles for R&D applications. Their technologies emphasize speed (<1 hour from sample to result), ease of use, reliability, and cost-effectiveness.

Therapeutic areas: Infectious DiseasesOther
Modalities: Molecular diagnostics platform (biochips, qPCR kits)OligonucleotidesNanoparticles
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on FRIZ Biochem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FRIZ Biochem.

Explore the full profile